RU2021115093A - Противораковые вакцины, нацеленные на boris, и способы их применения - Google Patents
Противораковые вакцины, нацеленные на boris, и способы их применения Download PDFInfo
- Publication number
- RU2021115093A RU2021115093A RU2021115093A RU2021115093A RU2021115093A RU 2021115093 A RU2021115093 A RU 2021115093A RU 2021115093 A RU2021115093 A RU 2021115093A RU 2021115093 A RU2021115093 A RU 2021115093A RU 2021115093 A RU2021115093 A RU 2021115093A
- Authority
- RU
- Russia
- Prior art keywords
- boris
- brother
- antigen
- vaccine
- nucleic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 7
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (17)
1. Молекула нуклеиновой кислоты, которая кодирует антиген-брат регулятора импринтированного сайта (BORIS), содержащий аминокислотную последовательность, содержащую мутации C276G, C279G, C304G, C307G, C332G, C335G, C361G, C364G, C389G, C392G, C417G, C420G, C447G, C450G, C477G, C480G, C505G, C508G, C533G, C536G, C565G, C568G, K603R и имеющую по меньшей мере 95% идентичность аминокислотной последовательности, приведенной в аминокислотах 19-680 SEQ ID NO: 2.
2. Применение молекулы нуклеиновой кислоты по п. 1 для лечения злокачественной опухоли.
3. Применение молекулы нуклеиновой кислоты по п. 1 для приготовления лекарственного средства для лечения злокачественной опухоли.
4. Экспрессионный вектор, содержащий молекулу нуклеиновой кислоты по п. 1.
5. Экспрессионный вектор по п. 4, содержащий плазмиду или вирусный вектор.
6. Антиген-брат регулятора импринтированного сайта (BORIS), содержащий аминокислотную последовательность, содержащую мутации C276G, C279G, C304G, C307G, C332G, C335G, C361G, C364G, C389G, C392G, C417G, C420G, C447G, C450G, C477G, C480G, C505G, C508G, C533G, C536G, C565G, C568G, K603R и имеющую по меньшей мере 95% идентичность аминокислотной последовательности, приведенной в аминокислотах 19-680 SEQ ID NO: 2.
7. Вакцина для лечения и/или предотвращения злокачественной опухоли, эксрессирующей антиген-брат регулятора импринтированного сайта (BORIS), содержащая эффективное количество молекулы нуклеиновой кислоты по п. 1.
8. Вакцина для лечения и/или предотвращения злокачественной опухоли, эксрессирующей антиген-брат регулятора импринтированного сайта (BORIS), содержащая эффективное количество вектора по п. 4 или 5.
9. Вакцина по п. 7 или 8, дополнительно содержащая фармацевтически приемлемый наполнитель.
10. Вакцина по п. 7 или 8, дополнительно содержащая адъювант.
11. Вакцина по п. 10, где адъювант представляет собой IL-12, IL-15, IL-28 или RANTES.
12. Способ лечения субъекта с экспрессирующей антиген-брат регулятора импринтированного сайта (BORIS) раковой клеткой, включающий введение терапевтически эффективного количества вакцины по любому из пп. 7-11.
13. Способ по п. 12, где введение включает электропорацию.
14. Способ по п. 12, где введение происходит в одном или более мест у субъекта.
15. Способ вакцинации субъекта против экспрессирующей антиген-брат регулятора импринтированного сайта (BORIS) раковой клетки, включающий введение количества вакцины по любому из пп. 7-11, эффективного для индукции гуморального или клеточного иммунного ответа.
16. Способ по п. 15, где введение включает электропорацию.
17. Способ по п. 16, где введение происходит в одном или более мест у субъекта.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598274P | 2017-12-13 | 2017-12-13 | |
| US62/598,274 | 2017-12-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020122871A Division RU2759681C1 (ru) | 2017-12-13 | 2018-12-13 | Противораковые вакцины, нацеленные на boris, и способы их применения |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2021115093A true RU2021115093A (ru) | 2021-07-01 |
| RU2021115093A3 RU2021115093A3 (ru) | 2021-10-29 |
| RU2799786C2 RU2799786C2 (ru) | 2023-07-11 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| CN111479585A (zh) | 2020-07-31 |
| CA3083531A1 (en) | 2019-06-20 |
| US11154601B2 (en) | 2021-10-26 |
| BR112020011716A2 (pt) | 2020-11-17 |
| RU2759681C1 (ru) | 2021-11-16 |
| JP2024102226A (ja) | 2024-07-30 |
| KR20200096954A (ko) | 2020-08-14 |
| EP3723798A1 (en) | 2020-10-21 |
| AU2024201842A1 (en) | 2024-04-11 |
| RU2021115093A3 (ru) | 2021-10-29 |
| US20250057929A1 (en) | 2025-02-20 |
| US20210401958A1 (en) | 2021-12-30 |
| US20190175710A1 (en) | 2019-06-13 |
| JP7485600B2 (ja) | 2024-05-16 |
| JP2021506269A (ja) | 2021-02-22 |
| KR20240090538A (ko) | 2024-06-21 |
| EP3723798A4 (en) | 2021-11-17 |
| US12161706B2 (en) | 2024-12-10 |
| WO2019118765A1 (en) | 2019-06-20 |
| AU2018383663B2 (en) | 2023-12-21 |
| MX2020006218A (es) | 2020-08-31 |
| AU2018383663A1 (en) | 2020-07-23 |
| KR102668476B1 (ko) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ingolotti et al. | DNA vaccines for targeting bacterial infections | |
| RU2014144133A (ru) | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин | |
| US10799572B2 (en) | Consensus antigen constructs and vaccines made therefrom, and methods of using the same to treat malaria | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2016539946A5 (ru) | ||
| Zhang et al. | Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant | |
| CN105497886A (zh) | 乙肝核心抗原病毒样颗粒作为肿瘤治疗性疫苗载体的应用 | |
| JP2019508403A5 (ru) | ||
| Sallam et al. | Formulation‐based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives | |
| JP2014523436A (ja) | 交差防御性アレナウイルスワクチンおよびそれらの使用方法 | |
| FI3737397T3 (fi) | Prameen kohdistetut syöpärokotteet ja niiden käytöt | |
| JP2014139185A5 (ru) | ||
| CN109200270B (zh) | 一种能提高多肽疫苗对hpv感染肿瘤治疗效果的联合用药物及其应用 | |
| CN114366810B (zh) | 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用 | |
| Kraynyak et al. | Tapping the potential of DNA delivery with electroporation for cancer immunotherapy | |
| RU2021115093A (ru) | Противораковые вакцины, нацеленные на boris, и способы их применения | |
| Kim | Skin vaccination methods: gene gun, jet injector, tattoo vaccine, and microneedle | |
| WO2018057727A1 (en) | Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein | |
| Lisziewicz et al. | The potential of topical DNA vaccines adjuvanted by cytokines | |
| US12109258B2 (en) | Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections | |
| PH12020500194A1 (en) | Malaria vaccine | |
| JP2023155245A5 (ru) | ||
| Borgoyakova et al. | Approaches to improve the immunogenicity of plasmid DNA-based vaccines against COVID-19 | |
| TW201922226A (zh) | 經鼻ｂ型肝炎疫苗組成物及其製造方法 | |
| RU2021117812A (ru) | Противораковые вакцины, нацеленные на сурвивин, и их применения |